Pioneers in individualized genetic testing
Cell-free DNA (cfDNA) can be found in everyone’s blood. Not only do our own cells release it, so do fetal, tumor, and donor organ cells. Using a simple blood draw, our technology precisely detects each of these types of cfDNA providing the insight to proactively inform treatment.
With a track record of constant innovation over the last 15 years, our technology has performed more cfDNA tests than any other.
Our cell-free DNA technology platform
Our cutting-edge technology platform combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.
“We started with reproductive genetic screening, and now we’re applying our technology platform to cancer monitoring and assessing the health of transplant patients.”
Our cell-free DNA technology workflow
Panorama: More than 2 million cell-free DNA tests performed
Panorama is the only non-invasive prenatal test (NIPT) that uses cell-free DNA and unique SNP-based technology, making it the #1 NIPT test in the US.
Validated by >50 peer-reviewed publications and >250 technology patents
The analytic and clinical validity of our technology has been described in leading scientific journals, including Nature, Science, and JAMA. Natera is the leader in peer-reviewed published data across cfDNA applications.